Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH ANDREA MIYAHIRA
The Prostate Cancer Foundation: A Discussion with Andrea Miyahira

VIEW ALL PCF VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH KENNETH PIENTA
The Process of Metastasis in Prostate Cancer

VIEW ALL PCF VIDEOS

European Society for Medical Oncology 2018 Congress

European Society for Medical Oncology 2018 Congress

INTERVIEW WITH FRED SAAD
A Renewed Analysis of ERA 223

VIEW ALL ESMO VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Latest Videos
Featured Videos

ORLANDO, FL USA (UroToday.com) - The American Urological Association (AUA) guidelines recommend repeat TUR in patients with T1 tumors given the 30% risk of muscle invasive disease detection on re-staging.

The most recent practice guidelines from the AUA recommend intravesical therapy for the treatment of HGT1 disease, while the EAU guidelines categorize HGT1 disease as high-risk and recommend intravesical full-dose BCG instillation, with RC reserved for the treatment of specific subtypes of high-risk tumors. Despite evidence showing a high risk for tumor upstaging, the role of early radical cystectomy (RC) for HGT1 disease remains controversial.

auaDespite the wealth of compelling evidence in support of early RC for HGT1 disease, the vast majority of patients are still under treated; less than 5% of patients presenting with HGT1 disease undergo early RC. Dr. Charles Concodora and colleagues used the National Cancer Database to evaluate contemporary performance trends of early RC for T1HG disease and assess the burden of pathologic upstaging at the time of RC. Of over 53 000 patients diagnosed with T1HG disease, only 6.8% underwent early RC. Encouragingly, the proportion of patients undergoing RC increased over the study period (4.7% [1998] versus 9.2% [2010]). Following multivariable adjustment, Charlson/Deyo score, age, race/ethnicity, year of diagnosis, insurance, geographic region, and hospital type were associated with performance of early RC. Pathologic upstaging at RC occurred in 37.5% of patients, while 3.9% were down-staged to pT0 disease. In conclusion, HGT1 carcinoma of the bladder is a potentially lethal disease, and patients treated with early RC have a potential survival advantage. Among patients within the NCDB, the utilization of early RC has doubled from 1998 to 2010, but still remains at less than 10% for patients with HGT1 disease. 37.5% of patients that underwent early RC were pathologically upstaged to ≥ T2 disease, thus further supporting the role of early RC in select patients.

Click HERE to listen to Jeffrey J. Tomaszewski, MD, one of the authors of this study

Presented by Charles Concodora, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Fox Chase Cancer Center, Philadelphia, PA USA

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com

 

Clinical Trials
Searchable data base of currently enrolling clinical trials
Journals
Publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 3 Issue 3

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

@UroToday
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe

Calendar
Upcoming educational events
December 13-16, 2018 / ESMO Immuno-Oncology Congress 2018
ESMO Immuno-Oncology Congress 2018
January 17-19, 2019 /
SNMMI 2019 Mid-Winter Meeting